NEW YORK, April 10, 2017 /PRNewswire/ --
Companies in the Drug Manufacturers space manufacture and process pharmaceuticalproducts. Large companies benefit from their economies of scale in research, manufacturing, and marketing. Today, Stock-Callers.com takes a closer look at four major industry players: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Johnson
New York headquartered Pfizer Inc.'s shares finished Friday's session 0.03% lower at $34.10. A total volume of 13.95 million shares was traded. The stock has gained 0.15% in the last month, 2.89% over the previous three months, and 6.06% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 1.72% and 2.89%, respectively. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 53.80.
On March 31st, 2017, Pfizer announced that the US Food FDA has approved a supplemental New Drug Application for its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, IBRANCE® (palbociclib), based on the results from the confirmatory Phase 3 trial PALOMA-2. The FDA action converts the accelerated approval of IBRANCE to regular approval, and broadens the range of anti-hormonal therapy that may be administered with IBRANCE. PFE complete research report is just a click away and free at:
Shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. ended the day 0.17% lower at $63.13 with a total trading volume of 7.71 million shares. The stock has advanced 5.50% in the previous three months and 8.01% since the start of this year. The Company's shares are trading 3.34% above their 200-day moving average. Moreover, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 38.79.
On April 07th, 2017, Merck & Co. announced that the US FDA has issued a Complete Response Letter regarding the Company's Supplemental New Drug Applications for JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin HCl), and JANUMET XR® (sitagliptin and metformin HCl extended-release). With these applications, Merck is seeking to include data from TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) in the prescribing information of sitagliptin-containing medicines. The complimentary report on MRK can be downloaded at:
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's stock declined 0.10%, closing the session at $124.92. A total volume of 3.61 million shares was traded. The Company's shares have gained 8.12% in the previous three months and 9.15% on an YTD basis. The stock is trading 3.19% above its 50-day moving average and 6.22% above its 200-day moving average. Additionally, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 59.44.
On March 21st, 2017, Johnson & Johnson announced that it will host a conference call for investors at 8:30 a.m. ET on Tuesday, April 18th, 2017, to review first-quarter results. Dominic Caruso, Vice President, Finance and CFO, and Joseph J. Wolk, Vice President, Investor Relations, will host the call. The webcast is accessible on the Company's website. Sign up for your complimentary research report on JNJ at:
On Friday, shares in North Chicago, Illinois-based AbbVie Inc. finished the session 0.71% higher at $65.54. A total volume of 5.41 million shares was traded. The stock has gained 1.61% in the last month, 3.78% over the previous three months, and 5.72% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 3.60% and 5.45%, respectively. Furthermore, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 61.31.
On March 22nd, 2017, research firm Societe Generale upgraded the Company's stock rating from 'Sell' to 'Hold'.
On April 07th, 2017, AbbVie announced detailed results from a Phase-2b clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy (estradiol/norethindrone acetate) compared to placebo. The data demonstrated that elagolix, with and without add-back therapy, met the primary efficacy endpoint of reduced heavy menstrual bleeding as compared to placebo. Get free access to your research report on ABBV at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All